Colon cancer metastasis inhibitor
AssigneeDaiichi Pharmaceutical Co., Ltd.
InventorsTetsu Akiyama, Yoshihiro Kawasaki, Rina Esashi
Life of this patent
Estimating the term…
Abstract
The present invention provides an agent for inhibiting metastasis of colorectal cancer and a method for inhibiting metastasis of colorectal cancer, which inhibit the function of Asef (i.e., binding activity to the APC gene product or guanine nucleotide exchange factor activity) that binds to the gene product of the tumor suppressor gene APC that plays an important role in tumorigenesis and in developmental processes, and/or inhibit the expression of the Asef gene.
Claims28
An agent for inhibiting metastasis of colorectal cancer, wherein the agent inhibits the function of Asef (APC-stimulated guanine nucleotide exchange factor) and/or inhibits the expression of the Asef gene.
2-25. (canceled)
A method for inhibiting metastasis of colorectal cancer, wherein the method comprises inhibiting the function of Asef (APC-stimulated guanine nucleotide exchange factor) and/or inhibits the expression of the Asef gene.
An agent for inhibiting metastasis of colorectal cancer, wherein the agent inhibits the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene or APC (Adenomatous Polyposis Coli) gene by the RNA interference on the expression of the gene.
A method for inhibiting metastasis of colorectal cancer, wherein the method comprises inhibiting the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene or APC (Adenomatous Polyposis Coli) gene by the RNA interference on the expression of the gene.
An oligonucleotide having the nucleotide sequence set forth in SEQ ID NO:
- 1, 2, 3, or 4 in the sequence listing.
Dependencies are inferred from the claim text.